Bremelanotide Approved to Treat Hypoactive Sexual Desire Disorder
July 6, 2019   

The U.S. Food and Drug Administration approved bremelanotide to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. Bremelanotide, a melanocortin 4 receptor agonist, is...
 Continue reading (Members only)
Remember to Sleep: Circadian Function in Alzheimer's Disease
July 2, 2019   

Alzheimer's disease affects approximately 44 million individuals worldwide. This age-related disease is characterized by accumulation of extracellular plaques composed of beta-amyloid protein, intracellular neurofibrillary tangles composed of hyperphosporylated tau protein, severe neuronal loss, and aggressive neuroinflammation. There is currently...
 Continue reading (Members only)
Esketamine Nasal Spray Plus Oral Antidepressant for Relapse Prevention in Treatment-Resistant Depression
June 25, 2019   

In a recent phase 3, multicenter, double-blind, randomized withdrawal study, esketamine nasal spray plus an oral antidepressant was compared to an oral anti-depressant plus placebo nasal spray for treatment-resistant depression. The study was...
 Continue reading (Members only)
Not "At Ease": Sleep in US Military Members
June 18, 2019   

In a recent review article, researchers summarize what is known about sleep/wake patterns in the military as well as speculating about the impact of sleep/wake issues on functioning of service members and veterans...
 Continue reading (Members only)
Health Professional Associations Oppose DHHS Plans to Change Gender Identify Protections Under Section 1557
June 12, 2019   

The U.S. Department of Health and Human Services proposed regulatory reform related to regulations issued under Section 1557 of the Affordable Care Act. A letter was sent in response, signed by 31 healthcare professional associations, including the American Psychiatric Association..
 Continue reading
Cariprazine Now Approved for Full Spectrum of Bipolar I Disorder Symptoms
June 7, 2019   

The U.S. Food and Drug Administration has approved the supplemental new drug application for cariprazine for the treatment of depressive episodes associated with bipolar I disorder in adults. In the three studies submitted with the supplemental new drug application, including...
 Continue reading
Suicide Trends in Youths: Disproportionate Rise in Rates Among Females
June 1, 2019   

In a recent cross-sectional study using period trend analysis of United States (US) suicide victims aged 10-19 years old from January 1, 1975 to December 31, 2016 to investigate trends in suicide among US youth. Period trends in suicide rates by sex and...
 Continue reading (Members only)
Age and Mixed Features May Predict Next-Step Strategies for Depression Remission
May 25, 2019   

Approximately 2/3 of patients with major depressive disorder (MDD) do not achieve remission despite adequate treatment with an antidepressant. It would be of utmost benefit to clinicians to be able to predict which patients would do better with which specific next-step treatment strategies -whether it be switching to a different antidepressant, combination of two antidepressants, or augmentation with a psychotropic from another drug class -rather than relying on trial and error...
 Continue reading (Members only)
Transcranial Magnetic Stimulation in a Retired NFL Player with Repetitive Traumatic Brain Injury
May 19, 2019   

The recent development of individualized resting-state network mapping has revealed considerable interindividual variability in anatomical localization of brain networks identified by using resting-state-functional MRI..
 Continue reading (Members only)
Smartphone Apps for Mental Health: Are Privacy Practices Adequate?
May 13, 2019   

Smartphone (Android and iOS) applications ("apps") for mental health have a wealth of potential for assisting in monitoring symptoms and progress and increasing access to care. Into these apps, users often enter a plethora of personal information that they may or may not...
 Continue reading
Top of Page